A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of 24 Weeks of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2018
At a glance
- Drugs JNJ-56136379 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Janssen Sciences Ireland UC
- 08 Jan 2018 Planned End Date changed from 20 Jun 2020 to 25 Jun 2020.
- 08 Dec 2017 Planned End Date changed from 5 May 2021 to 20 Jun 2020.
- 08 Dec 2017 New trial record